Medscape News

Link Description
FDA Approves Dupilumab (Dupixent) for Eczema Designated a breakthrough therapy, dupilumab spares patients with moderate to severe eczema from the need to resort to systemic immunosuppressants and the higher risks they pose
Xeljanz Approved for Rheumatoid Arthritis in European Union Xeljanz has received marketing authorization from the European Commission for the treatment of patients with moderate-to-severe RA, providing a new oral treatment option for these
Premixed Insulin: Best Practice Strategies What are the pros and cons of using premixed insulin, both human and analog, in patients with type 2 diabetes? <br /> <i>Medscape Family Medicine</i
Trump and GOP &#39;Pull&#39; House Bill to Replace ACA A vote on the bill was postponed for the second day in a row as President Trump and House Speaker Ryan could not win over enough Republican critics for passage. <br /> <i>Medscape
CHMP Backs Orphan Drug Refixia for Hemophilia B Refixia (nonacog beta pegol) is a recombinant coagulation factor IX product for the treatment and prophylaxis of bleeding in patients aged 12 years and older with hemophilia B. <
Gaslighting the Medical Literature How predatory publishing can make you doubt the facts (and your sanity), and a potentially revolutionary solution. <br /> <i>Medscape Internal Medicine</i
Morning Report: Fish Oil and Heart Disease--Science Advisory Dr Arefa Cassoobhoy highlights one of the week's important news stories for primary care. <br /> <i>Medscape Internal Medicine</i
CHMP Backs Trumenba for Meningococcal Disease Prevention The Committee for Medicinal Products for Human Use recommended marketing authorization for Trumenba for immunization against invasive meningococcal disease caused by meningococcal
CBO: Amended ACA Replacement Bill Doesn&#39;t Improve Coverage The bill still will increase the number of uninsured by 24 million by 2026, the CBO said. Meanwhile, a vote scheduled for today has been delayed. <br /> <i>Medscape Medical News</
More Than 80,000 EpiPens Recalled Overseas The company that markets EpiPens said the recalled devices may fail to inject its potentially life-saving dose of epinephrine into a patient experiencing anaphylactic shock. <br